Medical Pharmaceuticals

Claremont McKenna College Student Alvin Villarosa ’25 named Barry Goldwater Scholar

by

CLAREMONT, Calif., April 30, 2024 /PRNewswire/ — Alvin Villarosa ’25, a Claremont McKenna College Science Management major with a concentration in neuroscience, has been awarded the Barry Goldwater Scholarship, the highest governmental honor for undergraduate students pursuing a degree in science, technology, engineering, or math (STEM). Awarded to college sophomores and juniors who show exceptional promise … Read more

Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020

by

TAIPEI, April 30, 2024 /PRNewswire/ — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled, single-center, single, and multiple ascending oral dose study to evaluate the safety, tolerability, and pharmacokinetics of FP-020 in healthy … Read more

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024

by

BOSTON, April 10, 2024 /PRNewswire/ — Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2024 financial results at 6:00 am ET on Thursday, May 9, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET … Read more

Texaský ústav srdečních arytmií při Lékařském centru svatého Davida jako první v USA využívá systém ablace pulzním polem schválený ze strany FDA USA – čeština USA – English USA – English Middle East – Arabic Indonesia – Bahasa

by

AUSTIN, Texas, 10. dubna 2024 /PRNewswire/ – Elektrofyziologové z Texaského institutu srdečních arytmií (TCAI) při Lékařském centru svatého Davida začali jako první v zemi používat nový systém ablace pulzním polem (PFA) k léčbě pacientů s paroxysmální a perzistující fibrilací síní, srdeční arytmií, která postihuje miliony lidí po celém světě. Stalo se tak ihned poté, co … Read more

Manufacturing PMI® at 47.8%; February 2024 Manufacturing ISM® Report On Business®

by

New Orders; Backlogs Contracting; Production; Employment Contracting; Supplier Deliveries Slowing; Raw Materials Inventories Contracting; Customers’ Inventories Too Low; Prices Increasing; Exports and Imports Growing TEMPE, Ariz., March 1, 2024 /PRNewswire/ — Economic activity in the manufacturing sector contracted in February for the 16th consecutive month following one month of “unchanged” status (a PMI® reading of 50 percent) and … Read more

Younger Age of Primary ACL Injury, Decreased Time to Return to Sport Significantly Increases Risk of Secondary ACL Injury in Adolescent Athletes

by

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ — In adolescent athletes who underwent anterior cruciate ligament reconstruction (ACLR), the younger the athlete at the time of primary ACLR and an earlier return to sport (RTS) were significantly associated with an increased rate of secondary ACL injuries, according to new study presented at the 2024 Annual Meeting … Read more

Autism Specialists to Host Grand Opening of New Wisconsin Clinic for Young Children

by

EAU CLAIRE, Wis., Feb. 5, 2024 /PRNewswire/ — Caravel Autism Health, a leader in the diagnosis and treatment of young children on the autism spectrum, is hosting a ribbon-cutting on February 6 to celebrate the grand opening of a new, state-of-the-art autism therapy clinic. Autism experts at this new clinic at 4232 London Road in … Read more

Colposcopy Devices Global Market Likely to Exhibit Substantial Growth at a CAGR of ~5% by 2028, Predicts DelveInsight

by

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ — The surge in colposcopy device demand is mainly driven by a growing incidence of cervical disorders like cervical cancer and inflammatory alterations in the vulva, vagina, and cervix. Additionally, factors such as heightened awareness of early diagnosis, a growing embrace of advanced technologies, continuous product introductions and approvals, … Read more

Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation

by

Statistically significant reduction in donor-specific antibodies (DSAs) observed among imlifidase patients within five days of treatment as compared to standard of care LUND, Sweden, Dec. 14, 2023 /PRNewswire/ — Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today announced full results from the 16-HMedIdeS-12 phase 2 trial in patients with antibody mediated rejection (AMR) episodes following a … Read more